NAYA Therapeutics

What NAYA Therapeutics does

NAYA Therapeutics is a clinical-stage biopharmaceutical company headquartered in Miami, Florida (legal entity NAYA Biosciences, Inc.) that develops two synergistic oncology modalities: (1) Astatine-211 (²¹¹At) targeted alpha therapies — radiopharmaceuticals that deliver highly potent, short-range alpha radiation to cancer cells while sparing healthy tissue, leveraging the isotope's short 7.2-hour half-life, clean decay chain, chelatorless chemistry, and abundant bismuth-derived raw material; and (2) Flex-NK™ trispecific bifunctional antibodies that engage NK cells through NKp46 and CD16 while targeting tumor antigens such as GPC3, designed to reverse NK cell exhaustion and provide sustained cytotoxicity beyond antibody half-life. The company's initial strategic focus is on hepatocellular carcinoma (HCC) and multiple myeloma (MM), specifically for non-responders to standard-of-care and patients at risk of residual disease, with pipeline candidates including NY-303 (Flex-NK), NY-338, and a GPC3-targeted ²¹¹At alpha radioimmunotherapy.

NAYA operates a pre-revenue model with no commercialized products. Its business model centers on advancing assets through clinical development toward regulatory approval and commercialization, supported by a decentralized hub-and-spoke supply chain for ²¹¹At — established through exclusive-feeling alliances with IONETIX (US, August 2025), Atley Solutions (Europe, January 2026), and Alpha Nuclide (China, October 2025) — and reinforced by a European Research & Manufacturing Hub at the Paris-Saclay Cancer Cluster announced in January 2026. Distribution at commercial scale is expected to follow specialty pharmacy, hospital compounding, and direct-to-provider channels typical of radiopharmaceuticals.

The company's ownership history is unusual: it was acquired by INVO Fertility, Inc. in Q1 2025, triggering a $14.6 million non-cash impairment charge at the parent; INVO subsequently announced plans to divest its majority stake, and NAYA regained full rights to its next-generation cancer immunotherapies in May 2025. The company is led by CEO Daniel Teper (PharmD, MBA), with Jean-Marc Menat, MD leading European operations, Laurent Navarro, PhD as VP of Radiopharmaceutical R&D & CMC, and a Board that includes Ely Benaim, MD; Anne Lauvergeon, PhD; Rahul Singhvi, PhD, MBA; and Margarita Chavez, JD. Marketing and awareness activities are scientific and conference-driven (AACR, ASCO/ESMO, SITC, ASH, NOAR Europe), augmented by LinkedIn, YouTube educational webinars, and press releases via Access Newswire.

Name

NAYA Therapeutics

Legal name

NAYA Biosciences, Inc.

Website

https://nayatx.com

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

NAYA Therapeutics is a clinical-stage biopharmaceutical company developing two synergistic oncology modalities—astatine-211 targeted alpha therapies and Flex-NK trispecific NK-cell-engaging antibodies—initially targeting hepatocellular carcinoma and multiple myeloma patients who fail standard-of-care.

Ownership category

akta.pro rank

Product category

Radiopharmaceuticals and Cancer Immunotherapies

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB)

akta.pro secondary industries

Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx) (HLAIAGAC), NK Cell Therapies (HLAAABAD), Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA)

Keywords

• Targeted alpha therapy
• Cancer immunotherapy
• Bifunctional antibodies
• Radiopharmaceutical development
• Hepatocellular carcinoma therapy

Headquarters

HQ city

Miami

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Pre-Revenue / Clinical Stage: NAYA Therapeutics is a clinical-stage biopharmaceutical company. It has not yet commercialized any products and therefore has no product revenue. The company is focused on advancing its astatine-211 radiopharmaceutical pipeline and Flex-NK bifunctional antibodies through clinical development toward regulatory approval and commercialization.

Distribution channels1 record

Marketing channels5 records

Core offering

NAYA Therapeutics is a clinical-stage biopharmaceutical company that develops two synergistic oncology modalities: (1) Astatine-211 (²¹¹At) targeted alpha therapies — radiopharmaceuticals that deliver alpha particle radiation directly to cancer cells with short 7.2-hour half-life and minimal off-target toxicity, and (2) Flex-NK™ trispecific bifunctional antibodies — NK-cell-engaging antibodies that activate NK cells through NKp46 and CD16 and target tumors via antigens such as GPC3. Both modalities are initially being developed for hepatocellular carcinoma (HCC) and multiple myeloma (MM), targeting non-responders to standard-of-care.

Product overview

NAYA Therapeutics is a clinical-stage biopharmaceutical company pioneering next-generation cancer immunotherapies through two synergistic technology platforms: (1) Astatine-211 (²¹¹At) Targeted Alpha Therapies — leveraging the unique properties of the alpha-emitting radionuclide astatine-211 for targeted cancer treatment, and (2) FLEX-NK™ Bifunctional Antibodies — trispecific NK-cell-engaging antibodies targeting tumor antigens. The company is initially focused on hepatocellular carcinoma (HCC) and multiple myeloma (MM), with pipeline candidates including NY-303, NY-338, and a GPC3-targeted astatine-211 alpha radioimmunotherapy for HCC.

Differentiator

Problem solved

Functional benefit

Products and services

• Astatine-211 (²¹¹At) Targeted Alpha Therapies

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core.

• Atley SolutionscoreTechnology or Integration · 7 January 2026NAYA partnered with Atley Solutions to accelerate the development of its Astatine-211 radiopharmaceuticals. Atley Solutions is developing on-demand ²¹¹At availability through its supply chain infrastructure. CEO Milton Lönnroth discusses the path toward on-demand astatine-211 availability and the decentralized supply chain being built by Atley and other pioneers.
• Alpha NuclidecoreTechnology or Integration · 13 October 2025NAYA partnered with Alpha Nuclide to support clinical development in China for its GPC3-targeting Astatine-211 alpha therapy for hepatocellular carcinoma (HCC). Alpha Nuclide manufactures Astatine-211 in China as part of this alliance. The partnership highlights the importance of scalable isotope production and international logistics for the astatine-211 supply chain, with Alpha Nuclide CEO Yutian Feng emphasizing China's role in global biotech and the future of astatine-211.
• IONETIXcoreTechnology or Integration · 21 August 2025NAYA partnered with IONETIX to build a US production and supply network for Astatine-211 targeted alpha therapies. IONETIX provides astatine-211 manufacturing capability within the US, with VP of Medical Affairs David Eve discussing the potential of astatine-211 and the path forward for its supply chain.
• Alpha Nuclide (China Manufacturing Alliance)coreTechnology or IntegrationThe global TAT market report from ResearchAndMarkets.com identifies NAYA Therapeutics' alliance with Alpha Nuclide in China to manufacture Astatine-211 as a key strategic partnership, highlighting the importance of scalable isotope production and international logistics within the rapidly growing targeted alpha therapy market.

Scale indicators1 record

Recent moves8 records

Expansion highlights5 records

Direct peers

• Affimed: Affimed is a clinical-stage oncology company developing innate cell engagers (ICE®) that redirect NK cells to tumors via CD16A and targeting antigens such as GPC3 (similar to NAYA's Flex-NK). It is the closest mechanistic peer to NAYA's Flex-NK platform, particularly for GPC3-expressing tumors like HCC, and serves as a key read-across for NK-engager clinical data.
• Fusion Pharmaceuticals: Fusion was a clinical-stage targeted alpha therapy company focused on Actinium-225 conjugates for solid tumors before being acquired by AstraZeneca. It is a direct peer to NAYA's At-211 program because both pursue alpha-emitting radiopharmaceuticals for solid-tumor oncology in early clinical development.
• Point Biopharma: Point Biopharma was a clinical-to-commercial radiopharmaceutical developer focused on alpha and beta emitters (including Actinium-225 and Lutetium-177 programs) before being acquired by Eli Lilly. It is a direct peer for NAYA because both companies were built around isotope-agnostic manufacturing networks and ligand-based radio-oncology pipelines.
• ITM Isotope Technologies Munich: ITM is a privately held radiopharmaceutical company developing targeted radionuclide therapies (including alpha emitters) and operating proprietary isotope production (e.g., no-carrier-added Lu-177, Ac-225). It is a direct peer because it combines isotope manufacturing infrastructure with therapeutic radioligand pipelines, mirroring NAYA's At-211 production-plus-drug approach.
• Telix Pharmaceuticals: Telix is a commercial-stage radiopharmaceutical company developing diagnostic and therapeutic agents for oncology, including urological and other solid tumors. It is one of the most relevant direct peers to NAYA because both companies are building oncology radiopharmaceutical pipelines around isotope supply, partnered manufacturing, and theranostic-style targeting.

Emerging players

• Nkarta: Nkarta is a clinical-stage biotech engineering allogeneic and autologous NK cell therapies for hematologic and solid tumors, including multiple myeloma. It is an emerging peer to NAYA in the NK-cell oncology space, with overlap specifically in MM where NAYA's Flex-NK bifunctional antibodies also aim.
• Innate Pharma: Innate Pharma is a clinical-stage biopharma developing antibody-based and NK-cell-engaging therapies that leverage the NKp46 axis and other innate immune receptors — directly relevant to NAYA's Flex-NK design around NKp46 plus CD16. It is an emerging peer with overlapping mechanism, providing important mechanism validation and competitive benchmarks.
• Fate Therapeutics: Fate Therapeutics is a clinical-stage company developing off-the-shelf NK and T-cell therapies for cancer, including multiple myeloma. It is an emerging peer to NAYA in the NK-cell oncology space, providing a benchmark for cell-based modalities targeting MM while NAYA pursues an antibody-based NK-engager approach.

Broad incumbents

• Bayer (Algeta / Xofigo): Bayer markets Xofigo (Radium-223) and is investing across alpha-emitting and other radiopharmaceutical modalities. As a broad incumbent with global commercial reach and a legacy alpha-emitter asset, Bayer represents the commercialization benchmark and potential competitive entrant facing NAYA in HCC and MM.
• Novartis: Novartis is the established global leader in commercial radioligand therapy via Lutathera and Pluvicto and is investing heavily in next-generation alpha and beta emitters. It is a broad incumbent whose radioligand franchise sets the regulatory, manufacturing, and physician-adoption precedent that NAYA's At-211 program must compete within.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@NAYATherapeutics
• LinkedInlinkedin.com/company/naya-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NAYA Therapeutics